Search This Blog

Monday, July 1, 2024

AstraZeneca's COVID prevention drug application gets EU fast-track assessment

 AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.

The submission was based on positive data from a late-stage trial that showed the drug helped reduce the incidence of COVID-19 in immunocompromised patients.

https://www.msn.com/en-gb/health/other/astrazeneca-s-covid-prevention-drug-application-gets-eu-fast-track-assessment/ar-BB1pbK7H

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.